[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.16\u2033 global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.16\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d][et_pb_column tipo=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text _builder_version=\u201d4.20.4\u2033 header_2_font_size=\u201d24px\u201d header_2_line_height=\u201d1.4em\u201d background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d custom_padding =\u201d25px||||falso|falso\u201d global_colors_info=\u201d{}\u201d]<\/p>\n
Historicamente, pensava-se que o cancro oral era uma doen\u00e7a maligna relacionada com a idade; no entanto, a crescente preval\u00eancia de fatores de risco associados expande a demografia para grupos et\u00e1rios mais jovens. Esta mudan\u00e7a alarmante traz \u00e0 luz a import\u00e2ncia cr\u00edtica das estrat\u00e9gias de detec\u00e7\u00e3o proativa. Se o c\u00e2ncer oral n\u00e3o for tratado at\u00e9 os est\u00e1gios posteriores (III e IV), a taxa de sobreviv\u00eancia em cinco anos cai para menos de 50%.1<\/sup><\/p>\n O desafio reside no fato de que os sintomas normalmente passam despercebidos nos est\u00e1gios iniciais. Agora, mais do que nunca, os prestadores est\u00e3o numa corrida contra o tempo para diagnosticar e tratar os pacientes antes que a doen\u00e7a progrida para uma forma mais perigosa.<\/p>\n Se os prestadores conseguirem detectar o cancro oral nas fases iniciais (I e II), os resultados dos pacientes podem ser significativamente melhorados. Na verdade, a taxa m\u00e9dia de sobreviv\u00eancia nestas fases pode chegar a 90%. 1<\/sup> Da mesma forma, a detec\u00e7\u00e3o precoce evita a necessidade de grandes cirurgias reconstrutivas, pr\u00f3teses faciais e anos de terapia extensa para recuperar a fun\u00e7\u00e3o.<\/p>\n Para muitos pacientes, a jornada para um diagn\u00f3stico \u00e9 atrasada pela identifica\u00e7\u00e3o de sintomas em est\u00e1gio inicial e por um per\u00edodo prolongado de avalia\u00e7\u00e3o multifornecedor. Uma revis\u00e3o de escopo descobriu que os pacientes esperaram at\u00e9 seis meses pelo diagn\u00f3stico de carcinoma espinocelular oral. 2<\/sup> Este atraso no diagn\u00f3stico pode agravar ainda mais a condi\u00e7\u00e3o do paciente, limitando assim as op\u00e7\u00f5es de tratamento a opera\u00e7\u00f5es desfigurantes que prejudicam significativamente a qualidade de vida.<\/p>\n Embora a idade m\u00e9dia para o diagn\u00f3stico de c\u00e2ncer bucal seja 64 anos, mais de 20% casos s\u00e3o encontrados em pacientes com menos de 55 anos. 3<\/sup> Como tal, os prestadores devem estar atentos a sintomas e fatores de risco cl\u00ednicos em pacientes de todas as idades. A Oral Cancer Foundation recomenda exames anuais come\u00e7ando quando os pacientes atingem 18 anos de idade. 4<\/sup><\/p>\n No entanto, os pacientes que adotam determinados h\u00e1bitos de vida devem ser submetidos a exames regulares antes da recomenda\u00e7\u00e3o padr\u00e3o. Pacientes com hist\u00f3rico de uso de tabaco devem iniciar o rastreamento no in\u00edcio do uso, pois fumar multiplica o risco de c\u00e2ncer bucal em at\u00e9 dez vezes e o uso prolongado de tabaco sem fuma\u00e7a aumenta o risco em 50 vezes.5<\/sup><\/p>\n Manter-se \u00e0 frente do cancro oral requer uma avalia\u00e7\u00e3o consistente e um rastreio preciso. A Vigilant Biosciences\u00ae combina um profundo conhecimento do c\u00e2ncer bucal com experi\u00eancia l\u00edder em tecnologia de detec\u00e7\u00e3o para abrir um novo caminho no processo de diagn\u00f3stico. A equipe da Vigilant est\u00e1 trabalhando ativamente para fornecer as solu\u00e7\u00f5es mais avan\u00e7adas para ajudar os provedores a identificar, diagnosticar e tratar o c\u00e2ncer bucal mais cedo do que nunca.<\/p>\n Saiba mais sobre como a Vigilant Biosciences\u00ae est\u00e1 ajudando os fornecedores a acelerar a detec\u00e7\u00e3o do c\u00e2ncer bucal para melhorar os resultados dos pacientes em todo o mundo.<\/a><\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u201d4.20.4\u2033 text_font_size=\u201d14px\u201d header_2_font_size=\u201d24px\u201d header_2_line_height=\u201d1.4em\u201d background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d ]<\/p>\n Fontes<\/strong><\/p>\n 1. Funda\u00e7\u00e3o do C\u00e2ncer Oral. (nd). Funda\u00e7\u00e3o do C\u00e2ncer Oral. Recuperado em 15 de mar\u00e7o de 2023, de https:\/\/oralcancerfoundation.org\/?gclid=Cj0KCQjw2cWgBhDYARIsALggUhoUo4AK8qplxhAyEF1r8Pu0iL1nsi4f1WuhDGDsCqfFf8iNco4poz8aAj2FEALw_wcB<\/a> [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":" Historicamente, pensava-se que o cancro oral era uma doen\u00e7a maligna relacionada com a idade; no entanto, a crescente preval\u00eancia de fatores de risco associados expande a demografia para grupos et\u00e1rios mais jovens. Esta mudan\u00e7a alarmante traz \u00e0 luz a import\u00e2ncia cr\u00edtica das estrat\u00e9gias de detec\u00e7\u00e3o proativa. Se o cancro oral n\u00e3o for tratado at\u00e9 \u00e0s fases posteriores (III e IV), a taxa de sobreviv\u00eancia aos cinco anos cai [\u2026]<\/p>","protected":false},"author":3,"featured_media":359,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"Historically, oral cancer was thought to be an age-related malignancy; however, the growing prevalence of associated risk factors expands the demographic to younger age groups. This alarming shift brings to light the critical importance of proactive detection strategies. If oral cancer is left untreated until later stages (III and IV), the five-year survival rate drops to under 50%.1 \r\n\r\nThe challenge lies in the fact that symptoms are typically missed in early stages. Now more than ever, providers are in a race against time to diagnose and treat patients before the disease progresses to a more dangerous form.\r\n\r\nThe need for early detection\r\n\r\nIf providers succeed in catching oral cancer in the earlier stages (I and II), patient outcomes can be significantly improved. In fact, the average survival rate in these stages can reach 90%.1 Likewise, early detection obviates the need for major reconstructive surgery, facial prostheses, and years of extensive therapy to regain function.\r\n\r\nFor many patients, the journey to a diagnosis is delayed by identifying early-stage symptoms and extended multi-provider assessment period. One scoping review found that patients waited up to six months for an oral squamous cell carcinoma diagnosis.2 This diagnostic delay may further escalate a patient\u2019s condition, thereby limiting treatment options to disfiguring operations that significantly impair quality of life.\r\n\r\nPinpointing the right age\r\n\r\nAlthough the average age for an oral cancer diagnosis is 64, more than 20% of cases are found in patients younger than 55 years old.3 As such, providers should be on the lookout for symptoms and clinical risk factors in patients of all ages. The Oral Cancer Foundation recommends annual screenings starting once patients reach 18 years of age.4\r\n\r\nHowever, patients engaging in certain lifestyle habits should undergo regular screenings earlier than the standard recommendation. Patients with a history of tobacco use should start screening at the onset of use, as smoking multiplies the risk of oral cancer up to ten times and long-term smokeless tobacco use increases the risk 50-fold.5\r\n\r\nStaying ahead of oral cancer requires consistent evaluation and accurate screening. Vigilant Biosciences\u00ae pairs a deep understanding of oral cancer with leading expertise in detection technology to forge a new path in the diagnostic process. The Vigilant team is actively working to deliver the most cutting-edge solutions to help providers identify, diagnose, and treat oral cancer earlier than ever.\r\n\r\nLearn more about how Vigilant Biosciences\u00ae is helping providers accelerate oral cancer detection to improve patient outcomes around the world.\r\n____________________________________________________________________________\r\n\r\nSources\r\n\r\nOral Cancer Foundation. (n.d.). Oral Cancer Foundation. Retrieved March 15, 2023, from https:\/\/oralcancerfoundation.org\/?gclid=Cj0KCQjw2cWgBhDYARIsALggUhoUo4AK8qplxhAyEF1r8Pu0iL1nsi4f1WuhDGDsCqfFf8iNco4poz8aAj2FEALw_wcB \r\nMauceri, R., Bazzano, M., Coppini, M., Tozzo, P., Panzarella, V., Campisi, G. (2022). Diagnostic delay of oral squamous cell carcinoma and the fear of diagnosis: A scoping review. Frontiers in Psychology 13. \r\nKey Statistics for Oral Cavity and Oropharyngeal Cancers. (2023, January 18). American Cancer Society. https:\/\/www.cancer.org\/cancer\/oral-cavity-and-oropharyngeal-cancer\/about\/key-statistics.html\r\nScreening. (n.d.). Oral Cancer Foundation. Retrieved March 15, 2023, from https:\/\/oralcancerfoundation.org\/screening\/ \r\nRisk Factors. (n.d.). Oral Cancer Foundation. Retrieved March 15, 2023, from https:\/\/oralcancerfoundation.org\/cdc\/risk-factors\/","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-353","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\nA necessidade de detec\u00e7\u00e3o precoce<\/h2>\n
Determinando a idade certa<\/h2>\n
2. Mauceri, R., Bazzano, M., Coppini, M., Tozzo, P., Panzarella, V., Campisi, G. (2022). Atraso no diagn\u00f3stico do carcinoma espinocelular oral e o medo do diagn\u00f3stico: uma revis\u00e3o de escopo. Fronteiras em Psicologia 13.
3. Principais estat\u00edsticas para c\u00e2ncer de cavidade oral e orofar\u00edngeo. (2023, 18 de janeiro). Sociedade Americana do C\u00e2ncer. https:\/\/www.cancer.org\/cancer\/oral-cavity-and-oropharyngeal-cancer\/about\/key-statistics.html<\/a>
4. Triagem. (nd). Funda\u00e7\u00e3o do C\u00e2ncer Oral. Recuperado em 15 de mar\u00e7o de 2023, de https:\/\/oralcancerfoundation.org\/screening\/<\/a>
5. Fatores de Risco. (nd). Funda\u00e7\u00e3o do C\u00e2ncer Oral. Recuperado em 15 de mar\u00e7o de 2023, de https:\/\/oralcancerfoundation.org\/cdc\/risk-factors\/<\/a><\/p>\n